Frequent occurrence of abnormal E-cadherin/β-catenin protein expression in advanced gallbladder cancers and its association with decreased apoptosis

Oncology

Volumn 71, Issue 1-2, 2007, Pages 102-110

  Hirata, Kenro ^a   Ajiki, Tetsuo ^a   Okazaki, Taro ^a   Horiuchi, Hideki ^a   Fujita, Tsunenori ^a   Kuroda, Yoshikazu ^a  

^a KOBE UNIVERSITY   (Japan)

Author keywords

Catenin; Apoptosis; E cadherin; Gallbladder cancer

Indexed keywords

BETA CATENIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; UVOMORULIN;

ADENOCARCINOMA; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GALLBLADDER CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; WESTERN BLOTTING;

ADENOMA; AGED; APOPTOSIS; BETA CATENIN; BILIARY TRACT NEOPLASMS; CADHERINS; EPITHELIUM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GALLBLADDER NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 34247120155     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100478     Document Type: Article

References (42)

1. Curley S: Biliary tract cancer; in Pollock RE (ed): Surgical Oncology. Norwell, Kluwer Academic, 1997, pp 273-307.
2. Japan VSo. Tokyo, Japanese Ministry of Health and Welfare, Statistics Association, 1998.
3. Onoyama H, Yamamoto M, Tseng A, Ajiki T, Saitoh Y: Extended cholecystectomy for carcinoma of the gallbladder. World J Surg 1995;19:758-763.
4. Shimada H, Endo I, Sugita M, Masunari H, Fujii Y, Tanaka K, Misuta K, Sekido H, Togo S: Hepatic resection combined with portal vein or hepatic artery reconstruction for advanced carcinoma of the hilar bile duct and gallbladder. World J Surg 2003;27:1137-1142.
5. Kondo S, Nimura Y, Hayakawa N, Kamiya J, Nagino M, Uesaka K: Extensive surgery for carcinoma of the gallbladder. Br J Surg 2002;89:179-184.
6. Aberle H, Schwartz H, Kemler R: Cadherincatenin complex: protein interactions and their implications for cadherin function. J Cell Biochem 1996;61:514-523.
7. Rubinfeld B, Souza B, Albert I, Munemitsu S, Polakis P: The APC protein and E-cadherin form similar but independent complexes with α-catenin, β-catenin, and plakoglobin. J Biol Chem 1995;270:5549-5555.
8. Bailey T, Biddlestone L, Shepherd N, Barr H, Warner P, Jankowski J: Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia- adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol 1998;152:135-144.
9. Bongiorno PF, al-Kasspooles M, Lee SW, Rachwal WJ, Moore JH, Whyte RI, Orringer MB, Beer DG: E-cadherin expression in primary and metastatic thoracic neoplasms and in Barrett's oesophagus. Br J Cancer 1995;71:166-172.
10. Jawhari A, Jordan S, Poole S, Browne P, Pignatelli M, Farthing MJ: Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. Gastroenterology 1997;112:46-54.
11. Hiscox S, Jiang WG: Expression of E-cadherin,- α, β and γ-catenin in human colorectal cancer. Anticancer Res 1997;17:1349-1354.
12. Inagawa S, Itabashi M, Adachi S, Kawamoto T, Hori M, Shimazaki J, Yoshimi F, Fukao K: Expression and prognostic roles of β-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res 2002;8:450-456.
13. Ihara A, Koizumi H, Hashizume R, Uchikoshi T: Expression of epithelial cadherin and -α- and β-catenins in nontumoral livers and hepatocellular carcinomas. Hepatology 1996;23:1441-1447.
14. Gunji N, Oda T, Todoroki T, Kanazawa N, Kawamoto T, Yuzawa K, Scarpa A, Fukao K: Pancreatic carcinoma: correlation between E-cadherin and -α-catenin expression status and liver metastasis. Cancer 1998;82:1649-1656.
15. Sasatomi E, Tokunaga O, Miyazaki K: Spontaneous apoptosis in gallbladder carcinoma. Relationships with clinicopathologic factors, expression of E-cadherin, bcl-2 protooncogene, and p53 oncosuppressor gene. Cancer 1996;78:2101-2110.
16. Rashid A, Gao YT, Bhakta S, Shen MC, Wang BS, Deng J, Fraumeni JF Jr, Hsing AW: β-Catenin mutations in biliary tract cancers: a population-based study in China. Cancer Res 2001;61:3406-3409.
17. Yanagisawa N, Mikami T, Saegusa M, Okayasu I: More frequent β-catenin exon 3 mutations in gallbladder adenomas than in carcinomas indicate different lineages. Cancer Res 2001;61:19-22.
18. Chang HJ, Jee CD, Kim WH: Mutation and altered expression of β-catenin during gallbladder carcinogenesis. Am J Surg Pathol 2002;26:758-766.
19. Kimura Y, Furuhata T, Mukaiya M, Kihara C, Kawakami M, Okita K, Yanai Y, Zenbutsu H, Satoh M, Ichimiya S, Hirata K: Frequent β-catenin alteration in gallbladder carcinomas. J Exp Clin Cancer Res 2003;22:321-328.
20. Kohya N, Kitajima Y, Jiao W, Miyazaki K: Effects of E-cadherin transfection on gene expression of a gallbladder carcinoma cell line: repression of MTS1/S100A4 gene expression. Int J Cancer 2003;104:44-53.
21. 6-methylguanin-DNA methyltransferase and mismatch repair protein status in human gallbladder carcinoma. Int J Mol Med 2003;11:65-69.
22. Lowy AM, Knight J, Groden J: Restoration of E-cadherin/β-catenin expression in pancreatic cancer cells inhibits growth by induction of apoptosis. Surgery 2002;132:141-148.
23. Knuth A, Gabbert H, Dippold W, Klein O, Sachsse W, Bitter-Suermann D, Prellwitz W, Meyer zum Buschenfelde KH: Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol 1985;1:579-596.
24. Homma S, Hasumura S, Nagamori S, Kameda H: Establishment and characterization of a human gall bladder carcinoma cell line NOZ. Hum Cell 1988;1:95-97.
25. Litz J, Carlson P, Warshamana-Greene GS, Grant S, Krystal GW: Flavopiridol potently induces small cell lung cancer apoptosis during S phase in a manner that involves early mitochondrial dysfunction. Clin Cancer Res 2003;9:4586-4594.
26. Beneke S, Diefenbach J, Burkle A: Poly(ADP-ribosyl) ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions. Int J Cancer 2004;111:813-818.
27. Sobin LH, Wittekind C (eds): TNM Classification of Malignant Tumours, ed 6. New York, Wiley-Liss, 2002. 28 Ajiki T, Fujimori T, Onoyama H, Yamamoto M, Kitazawa S, Maeda S, Saitoh Y: K-ras gene mutation in gall bladder carcinomas and dysplasia. Gut 1996;38:426-429.
28. Sugimachi K, Taguchi K, Aishima S, Tanaka S, Shimada M, Kajiyama K, Sugimachi K, Tsuneyoshi M: Altered expression of β-catenin without genetic mutation in intrahepatic cholangiocarcinoma. Mod Pathol 2001;14:900-905.
29. Yamaguchi K, Chijiiwa K, Saiki S, Nishihara K, Takashima M, Kawakami K, Tanaka M: Retrospective analysis of 70 operations for gallbladder carcinoma. Br J Surg 1997;84:200-204.
30. Shimada H, Endo I, Togo S, Nakano A, Izumi T, Nakagawara G: The role of lymph node dissection in the treatment of gallbladder carcinoma. Cancer 1997;79:892-899.
31. Wakai T, Shirai Y, Yokoyama N, Nagakura S, Watanabe H, Hatakeyama K: Early gallbladder carcinoma does not warrant radical resection. Br J Surg 2001;88:675-678.
32. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Ferreira VM, Lopes CS: Association of E-cadherin and β-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas. Hum Pathol 2004;35:663-669.
33. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994;54:3929-3933.
34. Pignatelli M, Ansari TW, Gunter P, Liu D, Hirano S, Takeichi M, Kloppel G, Lemoine NR: Loss of membranous E-cadherin expression in pancreatic cancer: correlation with lymph node metastasis, high grade, and advanced stage. J Pathol 1994;174:243-248.
35. Ashida K, Terada T, Kitamura Y, Kaibara N: Expression of E-cadherin, α-catenin, β-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study. Hepatology 1998;27:974-982.
36. Day ML, Zhao X, Vallorosi CJ, Putzi M, Powell CT, Lin C, Day KC: E-cadherin mediates aggregation-dependent survival of prostate and mammary epithelial cells through the retinoblastoma cell cycle control pathway. J Biol Chem 1999;274:9656-9664.
37. Kantak SS, Kramer RH: E-cadherin regulates anchorage-independent growth and survival in oral squamous cell carcinoma cells. J Biol Chem 1998;273:16953-16961.
38. Kim K, Pang KM, Evans M, Hay ED: Overexpression of β-catenin induces apoptosis independent of its transactivation function with LEF-1 or the involvement of major G1 cell cycle regulators. Mol Biol Cell 2000;11:3509-3523.
39. Carmeliet P, Lampugnani MG, Moons L, Breviario F, Compernolle V, Bono F, Balconi G, Spagnuolo R, Oostuyse B, Dewerchin M, Zanetti A, Angellilo A, Mattot V, Nuyens D, Lutgens E, Clotman F, de Ruiter MC, Gittenberger-de Groot A, Poelmann R, Lupu F, Herbert JM, Collen D, Dejana E: Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999;98:147-157.
40. Matsuyoshi N, Hamaguchi M, Taniguchi S, Nagafuchi A, Tsukita S, Takeichi M: Cadherin-mediated cell-cell adhesion is perturbed by v-src tyrosine phosphorylation in metastatic fibroblasts. J Cell Biol 1992;118:703-714.
41. Roa I, Ibacache G, Melo A, Morales E, Villaseca M, Araya J, Roa J, Guzman P, de Aretxabala X: Subserous gallbladder carcinoma: expression of cadherin-catenine complex. Rev Med Chil 2002;130:1349-1357.
42. Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K: Expression of E-cadherin and β-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 2000;6:4789-4796.